ABSTRACT
The living will is a document that allows a patient to give instructions about the medical care they desire to receive at a future time. If consistent with Catholic teaching, it becomes a very effective tool for evangelization. A truly Catholic living will addresses five key principles: (1) the desire for pain relief, (2) assessing treatments as either ordinary or extraordinary, (3) providing nutrition and hydration, (4) prohibiting euthanasia, and (5) providing for spiritual care. The Catholic living will is not only individualized and patient-centered, it also avoids the dangers of a secular living will which deny patients proper end-of-life care.
ABSTRACT
This white paper, prepared by a working group of the Catholic Medical Association, provides a commentary on a new type of end-of-life document called a POLST form (Physician Orders for Life-Sustaining Treatment) as well as on its model (or "paradigm") for implementation across the United States. After an introductory section reviewing the origin, goals, and standard defenses of the POLST paradigm and form, the paper offers a critical analysis of POLST, including an analysis of the risks that POLST poses to sound clinical and ethical decision-making. The paper ends with several recommendations to help Catholic healthcare professionals and institutions better address the challenges of end-of-life care with alternatives to POLST.
ABSTRACT
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microarray gene-expression technologies, are increasingly being applied to elucidate these sources of variability and thereby potentially increase drug development success rates. With the aim of enhancing understanding of the regulatory significance of such biomarker data by regulators and sponsors, the US Food and Drug Administration initiated a programme in 2004 to allow sponsors to submit exploratory genomic data voluntarily, without immediate regulatory impact. In this article, a selection of case studies from the first 5 years of this programme - which is now known as the voluntary exploratory data submission programme, and also involves collaboration with the European Medicines Agency - are discussed, and general lessons are highlighted.
Subject(s)
Drug Approval , Gene Expression Profiling , United States Food and Drug Administration , Alanine Transaminase/blood , Azetidines/adverse effects , Azetidines/therapeutic use , Benzylamines/adverse effects , Benzylamines/therapeutic use , Carcinoma, Renal Cell/diagnosis , Europe , Fluorouracil/adverse effects , Genetic Markers , Humans , International Cooperation , Kidney Neoplasms/diagnosis , Kidney Transplantation , Pharmacogenetics , Piperazines/pharmacokinetics , Piperazines/therapeutic use , Prasugrel Hydrochloride , Precision Medicine , Thiophenes/pharmacokinetics , Thiophenes/therapeutic use , United StatesABSTRACT
HIV-1, the etiologic agent of human AIDS, causes cell death in host and non-host cells via HIV-1 Vpr, one of its auxiliary gene product. HIV-1 Vpr can also cause cell cycle arrest in several cell types. The cellular processes that link HIV-1 Vpr to the cell death machinery are not well characterized. Here, we show that the C terminal portion of HIV-1 Vpr which encompasses amino acid residues 71-96 (HIV-1 Vpr(71-96)), also termed HIV-1 Vpr cell death causing peptide, is an activator of protein phosphatase-2A(1) when applied extracellularly to CD(4+) T cells. HIV-1 Vpr(71-96) is a direct activator of protein phosphatase-2A(1) that has been purified from CD(4+) T cells. Full length HIV-1 Vpr by itself does not cause the activation of protein phosphatase-2A(1) in vitro. HIV-1 Vpr(71-96) also causes the activation of protein phosphatase-2A(0) and protein phosphatase-2A(1) from brain, liver, and adipose tissues. These results indicate that HIV-1 can cause cell death of infected cells and non-infected host and non-host cells via HIV-1 Vpr derived C terminal peptide(s) which act(s) by cell penetration and targeting of a key controller of the cell death machinery, namely, protein phosphatase-2A(1). The activation of other members of the protein phosphatase-2A subfamily of enzymes which are involved in the control of several metabolic pathways in brain, liver, and adipose tissues by HIV-1 Vpr derived C terminal peptide(s) may underlie various metabolic disturbances that are associated with HIV-1 infection.
Subject(s)
CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/enzymology , Gene Products, vpr/metabolism , Gene Products, vpr/pharmacology , HIV-1/metabolism , Phosphoprotein Phosphatases/metabolism , CD4-Positive T-Lymphocytes/drug effects , Cell Death/drug effects , Cell Line, Tumor , Enzyme Activation , Humans , Peptide Fragments/pharmacology , Phosphoprotein Phosphatases/isolation & purification , Protein Phosphatase 2 , vpr Gene Products, Human Immunodeficiency VirusABSTRACT
Rapamycin is a powerful immunosuppressant that causes cell cycle arrest in T cells and several other cell types. Despite its important clinical role, the mechanism of action of rapamycin is not fully understood. Here, we show that rapamycin causes the activation of protein phosphatase-2A1 which forms a complex with proliferation cell nuclear antigen (PCNA) in a CD4+ T cell line. Rapamycin also induces PCNA translocation from the cytoplasm to the nucleus, an effect which is antagonized by okadaic acid, an inhibitor of type 2A protein phosphatases. These findings provide evidence for the existence of a signal transduction pathway that links a rapamycin-activated type 2A protein phosphatase to the control of DNA synthesis, DNA repair, cell cycle, and cell death via PCNA.